Equities analysts expect that XOMA Corp (NASDAQ:XOMA) will report $630,000.00 in sales for the current quarter, Zacks reports. Two analysts have provided estimates for XOMA’s earnings, with estimates ranging from $290,000.00 to $970,000.00. XOMA reported sales of $2.26 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 72.1%. The firm is expected to report its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that XOMA will report full year sales of $10.14 million for the current year, with estimates ranging from $8.78 million to $11.50 million. For the next fiscal year, analysts expect that the company will post sales of $4.75 million, with estimates ranging from $900,000.00 to $8.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that cover XOMA.
XOMA (NASDAQ:XOMA) last posted its earnings results on Monday, May 6th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.33. XOMA had a negative return on equity of 51.66% and a negative net margin of 48.62%. The business had revenue of $8.13 million during the quarter, compared to analyst estimates of $3.23 million.
In other XOMA news, insider Value Fund L. P. Biotechnology purchased 27,913 shares of XOMA stock in a transaction that occurred on Tuesday, May 14th. The stock was purchased at an average price of $14.63 per share, with a total value of $408,367.19. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bvf Partners L. P/Il purchased 10,300 shares of XOMA stock in a transaction that occurred on Friday, May 10th. The stock was acquired at an average cost of $14.57 per share, with a total value of $150,071.00. The disclosure for this purchase can be found here. Insiders purchased 42,010 shares of company stock valued at $612,963 in the last three months. 9.89% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. California Public Employees Retirement System lifted its holdings in XOMA by 11.5% during the 4th quarter. California Public Employees Retirement System now owns 11,860 shares of the biotechnology company’s stock worth $150,000 after buying an additional 1,220 shares during the last quarter. Pennsylvania Trust Co bought a new position in XOMA during the 1st quarter worth approximately $3,531,000. Bank of New York Mellon Corp lifted its holdings in XOMA by 19.0% during the 4th quarter. Bank of New York Mellon Corp now owns 60,173 shares of the biotechnology company’s stock worth $761,000 after buying an additional 9,613 shares during the last quarter. BlackRock Inc. lifted its holdings in XOMA by 12.4% during the 4th quarter. BlackRock Inc. now owns 508,672 shares of the biotechnology company’s stock worth $6,434,000 after buying an additional 56,130 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in XOMA by 9.9% during the 4th quarter. Two Sigma Advisers LP now owns 32,195 shares of the biotechnology company’s stock worth $407,000 after buying an additional 2,905 shares during the last quarter. 48.51% of the stock is currently owned by institutional investors.
XOMA stock opened at $15.89 on Wednesday. The company has a current ratio of 7.20, a quick ratio of 7.20 and a debt-to-equity ratio of 1.13. XOMA has a 1 year low of $11.02 and a 1 year high of $25.99. The firm has a market capitalization of $136.82 million, a price-to-earnings ratio of -9.99 and a beta of 1.58. The company has a 50-day moving average of $16.85.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
See Also: Google Finance Portfolio Tips and Tricks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.